Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Breast Neoplasms 309Neoplasms 269Prostatic Neoplasms 189Precursor Cell Lymphoblastic Leukemia-Lymphoma 186Lymphoma 184Leukemia, Lymphocytic, Chronic, B-Cell 161Melanoma 158Leukemia 154Lymphoma, Non-Hodgkin 149Leukemia, Myeloid, Acute 149Brain Neoplasms 143Carcinoma, Non-Small-Cell Lung 141Lymphoma, Large B-Cell, Diffuse 128Colonic Neoplasms 128Lymphoma, Follicular 123Burkitt Lymphoma 119Ovarian Neoplasms 117Lung Neoplasms 116Glioblastoma 116Lymphoma, Mantle-Cell 114Unspecified Adult Solid Tumor, Protocol Specific 107Rectal Neoplasms 103Sarcoma 102Multiple Myeloma 102Gliosarcoma 102Hodgkin Disease 97Carcinoma, Renal Cell 97Lymphoma, B-Cell, Marginal Zone 96Astrocytoma 95Carcinoma, Ovarian Epithelial 93

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NIH × Fractures, Spontaneous × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡